Compare · ABT vs APUS
ABT vs APUS
Side-by-side comparison of Abbott Laboratories (ABT) and Apimeds Pharmaceuticals US Inc. (APUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and APUS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 26747.4x APUS ($6.8M).
- ABT has been more active in the news (13 items in the past 4 weeks vs 9 for APUS).
- ABT has more recent analyst coverage (25 ratings vs 0 for APUS).
- Company
- Abbott Laboratories
- Apimeds Pharmaceuticals US Inc.
- Price
- -
- -
- Market cap
- $181.14B
- $6.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 13
- 9
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest APUS
- NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide
- SEC Form 8-K filed by Apimeds Pharmaceuticals US Inc.
- MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure
- MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media
- MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.